Paper Details

  1. Home
  2. Paper Details

[Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension].

Author: AmielA, BoutaudP, CiberM A, DemangeJ, HerpinD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Betaxolol was shown to have a more prolonged antihypertensive effect on exercising heart rate and blood pressure compared to atenolol, suggesting its potential for treating hypertension associated with physical activity.
Paper Details　
Original Abstract of the Article :
Sixteen patients with mild to moderate hypertension were randomized to receive either atenolol 100 mg a day (group A: 2 females, 6 males, mean age 42.3 years) or betaxolol 20 mg a day (group B: 8 males, mean age 49.3 years), both drugs given once daily for one month with a wash out on the 5th day. P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2892458

データ提供：米国国立医学図書館（NLM）

Comparative Pharmacoclinical Study: Atenolol vs. Betaxolol in Hypertension

The field of [Hypertension Management] often involves the careful selection of [beta-blockers]. This study investigates the comparative pharmacoclinical effects of two beta-blockers, atenolol and betaxolol, in patients with mild to moderate hypertension. The research design involved randomizing 16 patients to receive either atenolol 100 mg/day or betaxolol 20 mg/day for a month. The results indicate that both drugs effectively reduced blood pressure, though the maximal effect occurred earlier with atenolol (1st day) compared to betaxolol (4th day). The duration of the antihypertensive action at rest appeared similar for both drugs, but betaxolol's effects on exercising heart rate and blood pressure were more prolonged. The study also found a positive correlation between plasma drug levels and the percentage of peak systolic blood pressure reduction, with this correlation being stronger for atenolol than betaxolol.

Atenolol and Betaxolol: Comparative Pharmacokinetic Profiles

This study provides valuable insights into the pharmacokinetic profiles of atenolol and betaxolol, two commonly used beta-blockers for hypertension management. The research highlights the differences in their time to maximal effect, duration of action, and correlation with plasma drug levels.

Understanding Medication Options: Tailoring Treatment to Individual Needs

This research underscores the importance of considering individual factors when selecting medication for hypertension management. The study's findings suggest that the choice between atenolol and betaxolol should be guided by factors such as the desired time course of action, the potential impact on exercise tolerance, and individual patient characteristics.

Dr.Camel's Conclusion

Like a discerning traveler choosing the best route through a vast desert, healthcare providers must carefully consider the nuances of different medication options. This research provides valuable guidance for choosing the most appropriate beta-blocker for hypertension management, taking into account the unique needs and characteristics of each patient.

Date :
  1. Date Completed 1988-02-12
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

2892458

DOI: Digital Object Identifier

2892458

SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.